Cerus(US:CERS)2025-02-20 21:01Revenue Growth - Preliminary full-year 2024 product revenues totaled $180.3 million, representing a 15% increase over 2023 results and exceeding the prior guidance of $177-$179 million[1][2] - The IFC revenue for full-year 2024 was $9.2 million, reflecting a significant growth of 42% compared to 2023[2] - For full-year 2025, product revenues are expected to be between $194 million and $200 million, indicating a year-over-year growth of 8% to 11%[1][3] - The first quarter of 2025 is projected to see product revenue growth of approximately 10% to 15% compared to the first quarter of 2024[3] - Total product revenue for the fourth quarter of 2024 was $50.8 million, a 9% increase from $46.8 million in the fourth quarter of 2023[6] - The platelet revenue for the full year 2024 was $171.1 million, up 14% from $149.9 million in 2023[6] Product Launch and Expansion - The company plans to launch the LED Illuminator in Europe and anticipates further geographic expansion[3] - The INTERCEPT Blood System remains the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma[7] Financial Position - The company continues to strengthen its financial position to support future growth initiatives[4] - Cerus is currently finalizing its full financial results for the year ended December 31, 2024, with preliminary results subject to change[12]